Differential Urinary MicroRNA Expression Analysis of MiR-1, MiR-215, MiR-335, Let-7a in Childhood Nephrotic Syndrome

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2022 May 13

PMID 35553329

Authors

Mohanapriya Chinambedu Dandapani

Vettriselvi Venkatesan

Pricilla Charmine

Sangeetha Geminiganesan

Sudha Ekambaram

Affiliations

Soon will be listed here.

Abstract

Background: Recently, urinary exosomal miRNAs are gaining increasing attention as their expression profiles are often associated with specific diseases and they exhibit great potential as noninvasive biomarkers for the diagnosis of various diseases. The present study was aimed to evaluate the expression status of selected miRNAs (miR-1, miR-215-5p, miR-335-5p and let-7a-5p) in urine samples from children with NS [steroid sensitive (SSNS)] and [steroid resistant (SRNS)] along with healthy control group.

Methods: MicroRNA isolation was carried out in urine samples collected from SSNS (100 nos), SRNS (100 nos), and healthy controls (50 nos) using MiRNeasy Mini Kit, followed by cDNA conversion for all the four selected miRNAs using Taqman advanced miRNA cDNA synthesis kit and their expression was quantified by Taqman Advanced miRNA assay kits using Real Time PCR Machine and Rotogen-Q in SSNS and SRNS patients and healthy control subjects.

Results: Quantification of all the four miRNAs (miR-1, mir-215, miR-335, let-7a) were found to be upregulated in both SSNS and SRNS as compared to control group. Further, the comparison of microRNAs within the case groups revealed significant downregulation of three microRNAs-miR-1, miR-215, miR- 335 and upregulation of let-7a in SRNS group as compared to SSNS. The t-test performed for all the four miRNAs was found to be statistically significant.

Conclusions: The aberrant expression of all the four microRNAs in both SSNS and SRNS as compared to healthy subjects may serve as novel biomarkers to distinguish between NS and healthy controls. The differential expression of microRNA let-7a is useful to discriminate SSNS and SRNS.

Citing Articles

MicroRNA Biomarkers as Promising Tools for Early Colorectal Cancer Screening-A Comprehensive Review.

Santos D, Gaiteiro C, Santos M, Santos L, Dinis-Ribeiro M, Lima L Int J Mol Sci. 2023; 24(13).

PMID: 37446201 PMC: 10341417. DOI: 10.3390/ijms241311023.

References

Bagga A . Revised guidelines for management of steroid-sensitive nephrotic syndrome. Indian J Nephrol. 2010; 18(1):31-9. PMC: 2847730. DOI: 10.4103/0971-4065.41289. View

Bierzynska A, Saleem M . Recent advances in understanding and treating nephrotic syndrome. F1000Res. 2017; 6:121. PMC: 5302149. DOI: 10.12688/f1000research.10165.1. View

Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E . Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol. 2009; 24(8):1525-32. DOI: 10.1007/s00467-009-1138-5. View

Hjorten R, Anwar Z, Reidy K . Long-term Outcomes of Childhood Onset Nephrotic Syndrome. Front Pediatr. 2016; 4:53. PMC: 4879783. DOI: 10.3389/fped.2016.00053. View

Luo Y, Wang C, Chen X, Zhong T, Cai X, Chen S . Increased serum and urinary microRNAs in children with idiopathic nephrotic syndrome. Clin Chem. 2013; 59(4):658-66. DOI: 10.1373/clinchem.2012.195297. View

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View

Chen T, Wang C, Yu H, Ding M, Zhang C, Lu X . Increased urinary exosomal microRNAs in children with idiopathic nephrotic syndrome. EBioMedicine. 2018; 39:552-561. PMC: 6355644. DOI: 10.1016/j.ebiom.2018.11.018. View

Szeto C . Urine miRNA in nephrotic syndrome. Clin Chim Acta. 2014; 436:308-13. DOI: 10.1016/j.cca.2014.06.016. View

Erturk E, Cecener G, Egeli U, Tunca B, Tezcan G, Gokgoz S . Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations. Mol Cell Biochem. 2014; 395(1-2):77-88. DOI: 10.1007/s11010-014-2113-4. View

10.

Gao L, Yang Y, Xu H, Liu R, Li D, Hong H . MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4. Tumour Biol. 2014; 35(8):8309-18. DOI: 10.1007/s13277-014-2092-9. View

11.

Sun Z, Zhang Z, Liu Z, Qiu B, Liu K, Dong G . MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting ZEB2. Med Oncol. 2014; 31(6):982. DOI: 10.1007/s12032-014-0982-8. View

12.

Cao J, Cai J, Huang D, Han Q, Chen Y, Yang Q . miR-335 represents an independent prognostic marker in epithelial ovarian cancer. Am J Clin Pathol. 2014; 141(3):437-42. DOI: 10.1309/AJCPLYTZGB54ISZC. View

13.

Bai X, Ma Y, Ding R, Fu B, Shi S, Chen X . miR-335 and miR-34a Promote renal senescence by suppressing mitochondrial antioxidative enzymes. J Am Soc Nephrol. 2011; 22(7):1252-61. PMC: 3137573. DOI: 10.1681/ASN.2010040367. View

14.

Wang H, Li M, Zhang R, Wang Y, Zang W, Ma Y . Effect of miR-335 upregulation on the apoptosis and invasion of lung cancer cell A549 and H1299. Tumour Biol. 2013; 34(5):3101-9. DOI: 10.1007/s13277-013-0878-9. View

15.

Yang B, Huang J, Liu H, Guo W, Li G . miR-335 directly, while miR-34a indirectly modulate survivin expression and regulate growth, apoptosis, and invasion of gastric cancer cells. Tumour Biol. 2015; 37(2):1771-9. DOI: 10.1007/s13277-015-3951-8. View

16.

White N, Khella H, Grigull J, Adzovic S, Youssef Y, Honey R . miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer. 2011; 105(11):1741-9. PMC: 3242591. DOI: 10.1038/bjc.2011.401. View

17.

Ribal M . Molecular profiling of renal cancer: the journey to clinical application. Eur Urol. 2011; 59(5):731-3. DOI: 10.1016/j.eururo.2011.01.039. View

18.

Qi-Dong X, Yang X, Lu J, Liu C, Sun J, Li C . Development and Validation of a Nine-Redox-Related Long Noncoding RNA Signature in Renal Clear Cell Carcinoma. Oxid Med Cell Longev. 2021; 2020:6634247. PMC: 7781722. DOI: 10.1155/2020/6634247. View

19.

Wang Z, Jiang B, Jin S, Hu Z, Liu G . Compound Mutations of the COL4A3 including a Novel Allele Identified in a Patient with Alport Syndrome. Biomed Res Int. 2021; 2020:1626378. PMC: 7673930. DOI: 10.1155/2020/1626378. View

20.

Tao G, Martin J . MicroRNAs get to the heart of development. Elife. 2013; 2:e01710. PMC: 3833033. DOI: 10.7554/eLife.01710. View